Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Natural Remedies

AlphaRx And Gaia BioPharma Report Positive Efficacy Results In A Pre-Clinical Trial Of GAI-122 Injectable Nano-emulsion For Post-operative Delirium
AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia.
generic viagra online
Brain Section Multitasks, Handling Phonetics And Decision-Making
A front portion of the brain that handles tasks like decision-making also helps decipher different phonetic sounds, according to new Brown University research.
News of the day
Greater Boston Unites To Transform Health Care
A coalition of organizations representing healthcare stakeholders throughout Greater Boston has been selected by the Robert Wood Johnson Foundation (RWJF) to participate in a planning grant to become part of the Aligning Forces for Quality (AF4Q) initiative. AF4Q is the Foundation"s signature effort to lift the overall quality of healthcare in targeted communities, reduce racial and ethnic disparities, and provide models for national reform.
Endocrinology

LATITUDE Pharmaceuticals Initiates Two More Collaboration Studies For Its PG Depot

LATITUDE Pharmaceuticals, Inc. (LPI), a San Diego-based drug formulation developer, announced today that it has initiated two new collaboration programs for its Phospholipid Gel (PG) Depot drug delivery platform. The programs are designed to provide prolonged and peak-free pharmacokinetic profiles for 3 and 7 days following a subcutaneous injection for an antibiotic and a protein drug, respectively. The new studies bring the total to seven feasibility/license agreements that are applying the PG Depot to deliver small molecules, peptides, and proteins for pain, metabolic disease, anti-bacterial, and cardiovascular applications. Andrew Chen, PhD, LPI"s president, noted, "Our newest feasibility studies represent a growing validation of our PG Depot technology. Like our ongoing collaborations, the new programs aim to transform a cumbersome routine of multiple injections each day into a convenient once-daily or once-weekly format. Both pharma and biotech companies definitely see high value in simplifying parenteral drug administration and extending or resurrecting IP protection through novel delivery technology. The protein-friendly nature of the PG Depot will create many opportunities to convert biologics from daily to weekly injections." About PG Depot LPI"s proprietary PG Depot technology is a versatile parenteral drug delivery platform for small molecules and biological therapeutics that delivers 1-7 days of low burst, peak-free sustained drug release following a subcutaneous or intramuscular injection. The PG Depot is provided as a single-phase, ready-to-use, self-administration-capable gel that is injectable through fine (27G or smaller) needles. The gel is compatible with hydrophilic and hydrophobic small molecule drugs as well as peptides and proteins and can be manufactured using conventional processes. Because it is composed of FDA-approved injectable and biodegradable ingredients, the PG Depot has key advantages over other depot systems, which use new polymers or animal-derived materials and face ever-increasing safety hurdles at the FDA and other regulatory agencies. LATITUDE Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009